Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.54 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | BLVRB | P30043 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | PHLPP2 | Q6ZVD8 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL3476110 | 1.00 | MEN1 (0.66) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29454399 | 1.00 | MEN1 (0.66) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL10784910 | 0.94 | MEN1 (0.59) | MEN1KMT2ABLVRBPDE4AKDR | |
| Chrysamine G SCHEMBL15818024 | 0.93 | TDP1 (0.70) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL15201080 | 0.93 | MEN1 (0.79) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL29950230 | 0.91 | MEN1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL27985065 | 0.91 | MEN1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL1614891 | 0.90 | TDP1 (0.57) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL27727543 | 0.87 | PHLPP2 (0.60) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL428681 | 0.87 | PLCG1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5630 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332230-A1 | ULCERATIVE COLITIS TREATMENTS IN SELECTED PATIENTS | THERIVA BIOLOGICS INC (US) | 2025-10-30 | — | — | US | claimed |
| US-20250244340-A1 | DIAGNOSING AND TREATING A PATHOLOGICAL CONDITION OF THE INTESTINAL TRACT | MAGNOSTICS LIMITED (IE) | 2025-07-31 | — | — | US | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| EP-4531861-A1 | ULCERATIVE COLITIS TREATMENTS IN SELECTED PATIENTS | Theriva Biologics, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| CN-117567554-B | Gel factor and hydrogel loaded with anti-inflammatory agent as well as preparation methods and application thereof | 中国科学技术大学 | 2025-03-07 | — | — | CN | claimed |
| CN-118286469-B | Preparation method for nonmetallic organic magnetic resonance nano diagnosis and treatment agent | 中山大学·深圳 | 2024-12-20 | — | — | CN | claimed |
| WO-2024234393-A1 | FLEXIBLE INTELLIGENT WOOD HAVING RESPONSE FUNCTION, ACTUATOR, AND MANUFACTURING METHOD | 南京林业大学 | 2024-11-21 | — | — | WO | claimed |
| WO-2000028974-A1 | LOCAL DELIVERY OF DRUGS TO THE COLON FOR LOCAL TREATMENT OF COLONIC DISEASES | DEXXON LTD. (IL) | 2000-05-25 | — | — | WO | claimed |
| WO-1998043630-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0331471-B1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTIINFLAMMATORY DRUGS | Larsen, Claus Selch (DK) | 1992-12-16 | — | — | EP | claimed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | claimed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | claimed |